文献速递肾癌与肾肿瘤

大型生物库中肾癌的单基因与多基因风险研究

Monogenic and Polygenic Risk for Kidney Cancer in Two Large Biobanks.
PubMed 文献 · Eur Urol Oncol · 2026-03-20

该研究在UKB(N=452 208)和GHI(N=20 452)两个大型队列中,评估了15个核心RCC遗传基因的致病性变异(PV)和已发表的PRS(PGS004908)与肾癌风险的关联。结果显示,核心RCC基因PV和PRS均与肾癌风险显著相关,PRS可补充单基因PV进行风险分层,并在GHI中跨欧洲和非欧洲 ancestry 重复验证。

要点

  • 核心RCC基因PV和PRS均与肾癌风险显著相关,而22个其他癌症易感基因PV无显著关联。
  • 高PRS非携带者的肾癌绝对发病率高于低PRS的PV携带者。
  • 在临床风险因素基础上加入遗传风险因素显著改善判别能力(C统计量0.67 vs 0.65)。

核心结论

  • PRS在肾癌遗传风险评估中有意义地补充了单基因PV,并可能改善超越既定临床因素的风险分层。

研究设计与样本

  • 在UK Biobank(UKB;N=452 208)和Genomic Health Initiative(GHI;N=20 452)两个大型队列中评估肾癌与15个核心RCC遗传基因及22个其他癌症易感基因的PV、以及已发表PRS(PGS004908)的关联。
  • 采用Cox比例风险模型,以年龄为底层时间尺度进行时间至事件分析。

主要发现

  • 在UKB中,15个核心RCC基因的聚合PV与肾癌风险显著相关(p < 0.001),而22个癌症易感基因的PV无显著关联(p = 0.4)。
  • PRS作为连续变量与肾癌显著相关(p < 0.001),对应更高的年龄特异性风险和诊断随年龄更早累积。
  • 不同组合遗传风险分层间肾癌发病率存在显著差异;非携带者高PRS的绝对发病率高于PV携带者低PRS。
  • 在招募时无肾癌的受限队列中,将遗传风险因素加入临床风险因素显著改善判别能力(C统计量0.67 vs 0.65,p < 0.001)。
  • PRS与肾癌的关联在GHI的欧洲和非欧洲 ancestry 参与者中均得到重复验证。

临床怎么用

  • PRS可补充单基因PV用于肾癌遗传风险评估,可能改善超越既定临床因素的风险分层。
  • 结合罕见突变和多基因风险可提供更全面的肾癌风险评估,可能有助于早期筛查和预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathogenic variants (PVs) in monogenic genes and polygenic risk scores (PRS) have been associated with kidney cancer risk. However, their joint contributions in the general population remain unclear. DESIGN, SETTING, AND PARTICIPANTS: Associations of kidney cancer with PVs in 15 core renal cell carcinoma (RCC) hereditary genes and 22 other cancer-susceptibility genes, and a published PRS (PGS004908) were evaluated in two large cohorts: the United Kingdom Biobank (UKB; N = 452 208) and the Genomic Health Initiative (GHI; N = 20 452). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazards models were fitted using a time-to-event framework with age as the underlying time scale. RESULTS AND LIMITATIONS: In UKB, aggregated PVs in the 15 core-RCC genes, but not in the 22 cancer-susceptibility genes, were significantly associated with kidney cancer risk (p < 0.001 and p = 0.4, respectively). PRS, modeled as a continuous variable, was also significantly associated with kidney cancer (p < 0.001). These associations corresponded to a higher age-specific hazard and earlier accumulation of diagnoses across age. Substantial differences in kidney cancer incidence rates were observed across combined genetic risk strata; notably, non-carriers with high PRS had higher absolute incidence rates than PV carriers with low PRS. In a restricted cohort of participants free of kidney cancer at recruitment, addition of genetic risk factors to clinical risk factors significantly improved discrimination (C-statistic 0.67 vs 0.65, p < 0.001). The association of PRS with kidney cancer was replicated in the GHI across participants with both European and non-European ancestries. CONCLUSION: PRS meaningfully complements monogenic PVs in genetic risk assessment for kidney cancer and may improve risk stratification beyond established clinical factors. PATIENT SUMMARY: Many patients with kidney cancer do not carry rare inherited mutations. Our study shows that common genetic factors, captured in a PRS, can also identify high-risk individuals. Combining both rare mutations and common polygenic risks provides a more complete assessment of kidney cancer risk and may aid in earlier screening and prevention.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wei J, Mulford AJ, Shi Z, et al. Monogenic and Polygenic Risk for Kidney Cancer in Two Large Biobanks. Eur Urol Oncol. 2026. PMID: 41864770. doi:10.1016/j.euo.2026.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。